Novartis cries foul in India
The Spicy India IP blog is reporting that there has been a further twist in Novartis’s challenge to the Indian Patent Office’s decision not to grant protection to its anti-cancer drug Glivec. The drug company has formally objected to the presence of…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.